Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
March 1, 2021Open Access

Extended-Release Carvedilol in the Treatment of Hypertension: A Double-Blind, Randomized, Placebo-Controlled Trial.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Immediate-release carvedilol requires twice-daily dosing and may have low treatment compliance, prompting evaluation of a once-daily extended-release formulation in patients with hypertension.

Does once-daily extended-release carvedilol reduce systolic blood pressure in patients with untreated or uncontrolled hypertension?

Population

134 patients with untreated or uncontrolled hypertension

Comparison

Low-dose carvedilol ER vs high-dose carvedilol ER vs placebo

Design

Double-blind, randomized, placebo-controlled trial

Follow-up

8 weeks

Authors

KWKang-Ling WangCFChih-Yuan FangWLWen‐Ter Lai

Discussion

Loading...

Member takes

Overview

Carvedilol ER failed to lower office SBP or DBP versus placebo; leaves open questions on optimal dosing or formulation for once-daily use.

Structured PICO

Does once-daily extended-release carvedilol reduce systolic blood pressure in patients with untreated or uncontrolled hypertension?

P
Population
134 patients with untreated or uncontrolled hypertension
I
Intervention
Once-daily extended-release carvedilol (low-dose or high-dose) for 8 weeks
C
Comparator
Placebo
O
Outcome
Reduction in office SBP at 8 weekssurrogate

Extended-release carvedilol did not result in a greater reduction in either SBP or DBP compared with placebo in patients with hypertension.

Cite This Study

Wang et al. (2021) studied this question.

synapsesocial.com/papers/6a70f1868031ec7bb1dcad18https://doi.org/10.6515/acs.202103_37(2).20200914b
View Full Paper
Ask AI
Bookmark
Share